ClinicalTrials.Veeva
Menu

Find clinical trials for Non-Hodgkin Lymphoma in Berlin, BE

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Lymphoma
B-Cell Lymphoma
Diffuse Large B-Cell Lymphoma
Leukemia
Lymphoid Leukemia
B-Cell Chronic Lymphocytic Leukemia
Cancer

Non-Hodgkin Lymphoma trials near Berlin, BE, DEU:

Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma (BELINDA)

to Standard Of Care in adult patients with aggressive B-cell Non-Hodgkin Lymphoma after failure of rituximab and anthracyc...

Active, not recruiting
Non-Hodgkin Lymphoma
Drug: Tisagenlecleucel after optional bridging and lymphodepleting chemotherapy
Drug: Platinum-based immunochemotherapy followed in responding patients with high dose chemotherapy and autologous hematopoietic stem cell transplant (HSCT)

Phase 3

Novartis
Novartis

Berlin, Germany and 66 other locations

and young adult participants with recurrent or refractory classical Hodgkin lymphoma and non-Hodgkin lymphoma...

Enrolling
Hodgkin Disease
Lymphoma, Non-Hodgkin
Drug: Relatlimab
Drug: Nivolumab

Phase 1, Phase 2

Bristol-Myers Squibb (BMS)
Bristol-Myers Squibb (BMS)

Berlin, Germany and 73 other locations

The purpose of this study was to evaluate whether copanlisib in combination with rituximab is superior to placebo in combination with rituximab in pr...

Active, not recruiting
Lymphoma,Non-Hodgkin
Drug: Placebo
Drug: Copanlisib (Aliqopa, BAY80-6946)

Phase 3

Bayer
Bayer

Berlin, Germany and 188 other locations

Follicular lymphoma (FL), marginal zone lymphoma (MZL), and mantle cell lymphoma (MCL) are distinct histologic types of B-...

Active, not recruiting
Lymphoma, Non-Hodgkin
Drug: Rituximab
Drug: Lenalidomide

Phase 3

Celgene
Celgene

Berlin, Germany and 125 other locations

This study evaluates the addition of nivolumab to gemcitabine, oxaliplatin plus rituximab in case of B-cell lymphoma...

Active, not recruiting
Lymphoma, Non-Hodgkin
Drug: Gemcitabine
Drug: Rituximab

Phase 2, Phase 3

Universität des Saarlandes

Berlin, Germany and 76 other locations

cancer treatment and have also shown first encouraging results in Non-Hodgkin lymphomas. Based on these observations it is...

Enrolling
Marginal Zone Lymphoma
Drug: Rituximab
Drug: Pembrolizumab
University of Ulm

Berlin, Germany and 13 other locations

This Phase 3 multinational, randomized, double-blind study is designed to compare the efficacy and safety of the combination of ibrutinib and venetoc...

Active, not recruiting
Mantle-Cell Lymphoma
Drug: Ibrutinib
Drug: Venetoclax

Phase 3

Pharmacyclics
Pharmacyclics

Berlin, Germany and 119 other locations

in participants with relapsed/refractory diffuse large B-cell lymphoma, who are not eligible for high-dose chemotherapy and autologous stem ...

Enrolling
Diffuse Large B-cell Lymphoma
Genetic: MB-CART2019.1
Drug: R-GemOx or BR plus polatuzumab vedotin

Phase 2

Miltenyi Biotec
Miltenyi Biotec

Berlin, Germany and 53 other locations

Follicular Lymphoma (FL) is the second most common B-cell cancer and the most common type of cancer of lymphocytes. Unfortunately, this dise...

Enrolling
Follicular Lymphoma (FL)
Drug: Lenalidomide
Drug: Epcoritamab

Phase 3

Genmab
Genmab

Berlin, Germany and 253 other locations

The purpose of this study is to compare the efficacy and safety of fixed duration pirtobruitinib (LOXO-305) with VR (Arm A) compared to VR alone (Arm...

Enrolling
Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia
Drug: Venetoclax
Drug: Rituximab

Phase 3

Loxo Oncology
Loxo Oncology

Berlin, Germany and 196 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems